Study of the Pathogenicity and Humoral Immune Response Induced by BK Virus in Lung Transplant Recipients

Launched by UNIVERSITY HOSPITAL, STRASBOURG, FRANCE · Nov 12, 2019

Keywords

ClinConnect Summary

This clinical trial is focused on understanding how a virus called BK virus (BKV) affects patients who have received a lung transplant. BKV is a common virus that most people carry, but it can cause problems in those whose immune systems are weakened, like lung transplant recipients. The study aims to find out how often BKV becomes active and if it leads to any health issues in these patients. By learning more about how the body responds to BKV, researchers hope to identify ways to predict and manage any complications that may arise.

To participate in this study, you need to be over 18 years old and have received a lung transplant at Strasbourg University Hospital between June 30, 2018, and December 31, 2022. You also need to be able to provide written consent to take part. The study is not yet recruiting participants, but if you qualify, you will have the opportunity to contribute to important research that could improve the care of future lung transplant patients.

Gender

ALL

Eligibility criteria

• Inclusion criteria:
• • Lung transplant recipients in Strasbourg University Hospital between 30 June 2018 and 31 December 2022
• • Male or female patients, age over 18 years
• • Patient having provided informed written consent to take part in the study
• • Patient affiliated to Social Security
• Exclusion criteria:
• • Patient deprived of liberty, by judicial or administrative decision
• • Patient under legal guardianship
• • Impossibility to give complete information about this study to the patient